In this study, we investigated if treatment with the PARPi Olaparib and Rucaparib can improve the therapeutic efficacy of SSTR2-targeted PRRT in different SCLC models in vitro and in vivo. This evidence concerns the gene SSTR2 and small cell lung carcinoma.